Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 UCB to Acquire Ra Pharmaceuticals in $2.5B Transaction | Contract Pharma

What are you searching for?

Sign in
Breaking News

UCB to Acquire Ra Pharmaceuticals in $2.5B Transaction

Acquisition will add zilucoplan, a Phase III candidate to potentially compete with Alexion’s Soliris

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

UCB Pharma has entered an agreement to acquire Ra Pharmaceuticals in deal valued at $2.5 billion. The acquisition will add zilucoplan, a Phase III candidate to potentially compete with Alexion’s Soliris, a monoclonal antibody for the treatment of rare chronic blood disorders, paroxysmal nocturnal hemoglobinuria (PNH), and atypical hemolytic uremic syndrome. Soliris had sales of nearly $3.6 billion in 2018.
 
Ra’s zilucoplan is a once-daily, self-administered, subcutaneous C5 inhibitor in Phase III development for myasthenia gravis.

UCB also has a Phase III myasthenia gravis candidate with a different mechanism of action, and zilucoplan complements the company’s growth plan. UCB expects the acquisition to close by the end of 1Q20. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters